- Home
- AEI vs BDTX Comparison
AEI vs BDTX Comparison
Compare AEI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEI | BDTX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4M | 116.8M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AEI | BDTX |
|---|---|---|
| Price | $1.79 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 8.6K | ★ 691.3K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $16,238,200.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.85 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $1.46 |
| 52 Week High | $4.55 | $4.94 |
Technical Indicators
Market Signals| Indicator | AEI | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 75.48 |
| Support Level | $1.47 | $3.02 |
| Resistance Level | $2.10 | $3.37 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 38.00 | 90.95 |
Price Performance
Historical ComparisonAbout AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.